Yet the study authors do not dismiss LAM, instead they say “family planning, maternal health, child health and nutrition programming together must address this widespread misunderstanding of LAM among the general population broadly and among women of reproductive age more specifically”.

Unfortunately the view seems to be that LAM should be forgotten. We have other methods of contraception that work just as well and are more convenient for healthcare professionals. LAM is no longer included in the latest edition of the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2016). Cochrane says “LAM should be studied only if its advocation does not hamper the introduction of longer-term methods of contraception.” 4

The main problem with this approach is the impact of hormonal contraception on breastfeeding.

Breastfeeding counsellors and lactation consultants are increasingly concerned about the anecdotal reports they are receiving around the impact of hormonal contraception (including progesterone only) on milk supply.

Lactogenesis is triggered by the loss of progesterone when the placenta is delivered. Any retained placenta impacts on lactation hormones, so large doses of progesterone in the early postpartum period are an area for concern.

The Lancet report on breastfeeding5 noted:

“Our systematic reviews emphasise how important breastfeeding is for all women and children, irrespective of where they live and of whether they are rich or poor... Appropriate breastfeeding practices prevent child morbidity due to diarrhoea, respiratory infections, and otitis media [ear infections]. Where infectious diseases are common causes of death, breastfeeding provides major protection but even in high-income populations it lowers mortality from causes such as necrotising enterocolitis and sudden infant death syndrome.”

Supporting breastfeeding saves lives and improves child health in all countries. So it seems sensible to follow the Breastfeeding Network’s approach to postpartum contraception.

This includes advice that breastfeeding women avoid hormonal contraception for 21 days postpartum. If desired, a woman can then take the mini-pill for a month to check that her milk supply is not affected.

Any problems should be reported using the Yellow Card Scheme (i.e. the UK system for collecting information on suspected adverse drug reactions to medicines and medical devices). Only if breastfeeding is going well should long-acting hormonal methods such as depot medroxyprogesterone acetate or the implant be considered.

This staged approach might not always be appropriate, but improving the way we communicate about LAM and adopting a more cautious approach to hormonal contraception seem like good strategies for improving child and maternal health.

We look forward to hearing from those with an interest in both providing effective postpartum contraception and supporting breastfeeding.

Sarah Panzetta*
Fertility awareness practitioner (Fertility UK), London, UK; sarah@befertilityaware.co.uk

Emma Pickett
Lactation consultant (IBCLC), ABM Chair, Association of Breastfeeding Mothers (ABM), London, UK; emmapickettibclc@gmail.com

*Corresponding author

Twitter Follow Sarah Panzetta at @bfaware

Competing interests None declared.

REFERENCES


3 Fabic MS, Choi Y. Assessing the quality of data regarding use of the lactational amenorrhea method. Stud Fam Plann 2013;44:205–221.
